Navigation Links
Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
Date:9/18/2009

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase II clinical trial for patients with primary liver cancer, demonstrated promising Phase I efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products simultaneously shut-off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex Biotherapeutics is headquartered in San Francisco and has manufacturing, research and development activities based at the OHRI in Ottawa, Canada. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit www.jennerex.com .

About the Ottawa Regional Cancer Foundation

The Ottawa Regional Cancer Foundation is dedicated to increasing cancer survivorship in Eastern Ontario and works to fill the gaps in services. The Cancer Foundation aims to reduce wait times, increase access to the latest therapies, provide care closer to home and improve quality of life for cancer patients and their families. For more information, please visit www.ottawacancer.ca

About the Ottawa Hospital Research Institute

The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with t
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Jennerex Closes $5 Million First Tranche of Series C Financing
2. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
5. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
6. Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
7. EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application
8. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
9. ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development
10. Pacific Biometrics Completes $4 Million Debt Financing
11. Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...stCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglob...dthatithassubmittedaMAAtotheEuropeanMedicinesAgenc...nttherapyindevelopment,forthetreatmentofType1Gauch...laglucerasealfathathasbeensubmitted,withprevious,s...onaglobalsupplyshortageofthecurrentlyapprovedandma...
(Date:11/24/2009)...e/--HealthRoboticstodayannounced,thatithasformedan...rs.ThisrecentlyformedToronto-basedcompanywillopera...ket,install,andsupport,HealthRobotics,i.v.Roomofth...ctofferingsi.v.STATION(TM),i.v.SOFT(TM),andOMM(TM)...eonan"asneeded,basis"toitsstrategicpartnershipswit...
(Date:11/24/2009)...all/--CellTherapeutics,Inc.(CTI)(NasdaqandMTA:CTIC...ealthCareConference.TheconferencewillbeheldDecembe...esentonTuesday,December1at11:00a.m.EasternTimeinHo...onwillbeavailableat www.celltherapeutics.com ,andi...JaffrayHealthCareConference,NewYorkPalaceHotel,Hol...
(Date:11/23/2009)...communication, computation and more powerful ways ...e quantum states as carriers of information is an ...ve shown, mathematically, how to gently tease out ...ping the information intact. Their work is reporte... and highlighted with a Viewpoint in Physics ( ...
Breaking Biology Technology:Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...ical Animal Data Demonstrates Selective Survival A...after HIV Infection, RICHMOND, Calif., Sept. 18 /...(Nasdaq: SGMO ) announced today the presentation ...e made permanently resistant to,HIV infection by t...eases,(ZFN(TM)) and preferentially survive and exp...
...rings The New Face of Research - the New ISI Web o...nstitutions Throughout the Country, PHILADELPHIA ...The Thomson Corporation (NYSE: TOC ; TSX: TOC) an... worldwide research and,business communities, anno...a la Ciencia y la Tecnologia (FECYT) has renewed i...
...H TRIANGLE PARK, N.C., Sept. 18 ,Siemens Medical S...d Xintek Inc.,announce today that they have signed... in Research Triangle Park, N.C. The mission of th... a new multi-pixel X-ray source,technology for a b...ogo: http://www.newscom.com/cgi-bin/prnh/20070904...
Other Biology Technology:Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 2Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 4Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 5Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 2Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 3Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes 2
(Date:11/23/2009)...r 23, 2009 - The time of day matters to forest tre...produced by a research team led by Professor Malco...ice-principal for research and colleagues in the d...eorge campus. , Capitalizing on their previous... research team examined how poplar trees use their...
(Date:11/23/2009)... only swine vaccine available for the H1N1 virus h...th the virus. The vaccination marks the first time...ith the pandemic flu., Iowa State University,s H... the vaccine this summer and has been shipping pre...nd Illinois for several weeks., The latest vacci...
(Date:11/23/2009)...wo new studies reveal in unprecedented detail how ...emble new proteins and guide them toward their des...ecular dynamics flexible fitting (MDFF) to examine...t molecular partners. , The first study, in Pr...ncerns the intimate signaling between the ribosome...
Breaking Biology News(10 mins):Time of day matters to thirsty trees, U of T researcher discovers 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3COSHAR Foundation Promotes Importance of Timely Childhood Immunization at Black Family Reunion Celebration in Washington D C 56444 1COSHAR Foundation Promotes Importance of Timely Childhood Immunization at Black Family Reunion Celebration in Washington D C 56444 2BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 4954 1BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 4954 24 Balzan 2009 prize winners announced in Milan 56438 14 Balzan 2009 prize winners announced in Milan 56438 2
...rability during ePassports EAC Conform...ept. 9 After successful deployment,of their first...gain has,selected Entrust, Inc. (Nasdaq: ENTU ) t...ond-generation ePassport solution based on the Ext...ovenia becomes one of the first,countries in the w...
...so-called triglycerides in specialized fatty tissu...he delicate balance of the lipid metabolism gets o... leading to the dreaded fatty liver. This increase... metabolic syndrome known as "deadly quartet". Thi...d hypertension is regarded as the primary cause of...
... France,s presidency of the EU, Lille will play ho...e GMES (Global Monitoring for Environment and Secu...s relating to the environment, climate change, res...e services draw on data - mainly Earth observation...combined with socio-economic data, processed in su...
Other Biology News:Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 2Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 3Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 4Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 5Cortisol and fatty liver: Researchers find cause of severe metabolic disorders 2Major European program for the environment under the spotlight in Lille, France 2
Human Complement C1r from BIOPUR
...on Designer designs oligos for SYBR Green, TaqMan,...NASBA and FRET assays. Highly specific primers are...tomatically interpreting BLAST search results. Pri...condary structures identified by connecting to the...
...ists of the LVF-HL, LVF-CUVADPT, FHS-LVF, and the ... and low-pass Linear Variable Filters to create th...nter wavelength and adjustable bandpass. Each filt...and blocking band (99.8%). These filters -- with ...
Custom siRNA, HPLC purified, annealed from Ambion
Biology Products: